CSIMarket
 
Viking Therapeutics Inc   (VKTX)
Other Ticker:  
 
 
Price: $67.9500 $1.00 1.494%
Day's High: $68.48 Week Perf: -5.16 %
Day's Low: $ 65.50 30 Day Perf: -5.57 %
Volume (M): 2,096 52 Wk High: $ 99.41
Volume (M$): $ 142,396 52 Wk Avg: $25.28
Open: $66.26 52 Wk Low: $8.28



 Market Capitalization (Millions $) 6,785
 Shares Outstanding (Millions) 100
 Employees 11
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -81
 Cash Flow (TTM) (Millions $) 8
 Capital Exp. (TTM) (Millions $) 0

Viking Therapeutics Inc
Viking Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on the development of novel therapies for serious and life-threatening diseases. The company is headquartered in San Diego, California, and was founded in 201 Viking's goal is to develop innovative therapies that will improve the lives of patients suffering from metabolic and endocrine disorders, as well as other serious diseases.

The company's main focus is on the development of selective and orally available small molecule drugs that mimic the beneficial effects of naturally occurring hormones. The company's lead product candidate is VK5211, a novel treatment for muscle wasting and bone loss. This compound has shown promising results in early clinical trials and may have the potential to help patients with a range of debilitating conditions, including hip fracture recovery, cancer cachexia, and sarcopenia.

Viking's pipeline also includes VK2809, a thyroid beta receptor agonist designed to treat hypercholesterolemia and non-alcoholic fatty liver disease (NAFLD). Other pipeline candidates include VK0214, a thyroid beta receptor agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD), and VK0612, a second-generation thyroid beta receptor agonist for NAFLD and other metabolic disorders.

Viking Therapeutics has a unique research approach that leverages the best of both natural and synthetic compounds. The company's team of experienced scientists uses a combination of high-throughput screening, medicinal chemistry, and pharmacology to identify and optimize drug candidates. Viking has also established strategic partnerships with leading academic institutions and research organizations to accelerate the development and commercialization of their products.

In summary, Viking Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for serious and life-threatening diseases. The company's main focus is on the development of small molecule drugs that mimic the beneficial effects of naturally occurring hormones. Viking's pipeline includes products for muscle wasting, bone loss, hypercholesterolemia, NAFLD, and X-ALD. The company's research approach leverages the best of both natural and synthetic compounds, and the company has established strategic partnerships with leading academic institutions and research organizations to accelerate the development of their products.


   Company Address: 9920 Pacific Heights Blvd San Diego 92121 CA
   Company Phone Number: 704-4660   Stock Exchange / Ticker: NASDAQ VKTX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stock Offering

Viking Therapeutics' Successful Public Offering Strengthens Market Position and Drives Share Price Surge

Published Mon, Mar 4 2024 9:45 PM UTC



Viking Therapeutics, a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder therapies, has recently announced the successful closing of its public offering of common stock. With an option for underwriters to purchase additional shares exercised in full, the company's market position has been further bolstered. This press release...

Stock Offering

Viking Therapeutics Sets Sail with $550 Million Public Offering

Published Thu, Feb 29 2024 1:50 AM UTC

Viking Therapeutics Makes Major Move with $550 Million Public Offering
Viking Therapeutics, Inc. has made a significant announcement with the pricing of its $550 million public offering of common stock. This clinical-stage biopharmaceutical company, focused on developing therapies for metabolic and endocrine disorders, is taking a big step towards advancing its research ...

Viking Therapeutics Inc

Major Pharmaceutical Preparations Company Reports Contraction in Operating Behavior During Third Quarter of 2023

The financial results for Viking Therapeutics Inc (VKTX) have been recently announced, revealing an operating shortfall of $-27.265 million for the most recent fiscal period. This news has caused concern among shareholders and industry observers, as they eagerly await additional revenue sources to offset this significant loss.
It is worth noting that the Major Pharmaceutical Preparations industry, to which VKTX belongs, has also been experiencing its own challenges and uncertainties. As a result, the current operational behavior of VKTX has not been a top priority for shareholders. Instead, their focus has shifted towards the potential growth opportunities and revenue streams that the company can tap into in the near future.

Viking Therapeutics Inc

Dramatic Drop in Viking Therapeutics' Operations Stirs Concern as Q2 2023 Ends: Multi-Million Dollar Deficit Revealed

Viking Therapeutics Inc, a major player in the pharmaceutical preparations industry, recently released its second quarter financial results for 2023. As industry experts delve into these numbers, it becomes evident that the company is facing certain challenges as it strives to generate revenue.
For the quarter ending June 30, 2023, Viking Therapeutics Inc reported an operating deficit of $-23.74 million, a significant increase from the operating deficit of $-17.631 million recorded in the same quarter of the previous year. This highlights the company's struggle to generate profits from its operations.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com